Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

BMC Immunology is a prominent open-access journal published by BMC that has been at the forefront of immunological research since its inception in 2000. Based in the United Kingdom, this journal aims to advance the understanding of immune system functions and disorders through high-quality, peer-reviewed articles. With an impressive scope encompassing various facets of immunology, BMC Immunology has earned a Q3 ranking in the Immunology category according to the 2023 category quartiles, demonstrating its growing impact and relevance in the scientific community. Researchers and professionals will find valuable insights in its array of published works, spanning both foundational studies and innovative applications. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and advancement in the field. For those looking to stay updated on the latest developments in immunology, BMC Immunology stands as an essential resource for researchers, professionals, and students alike.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

Seminars in Immunopathology is a premier academic journal published by SPRINGER HEIDELBERG, focusing on the intricate relationships between immune responses and pathologies. With an ISSN of 1863-2297 and an E-ISSN of 1863-2300, this journal delivers cutting-edge research and insights to its readers, contributing significantly to the fields of immunology and allergy, as reflected in its Q1 quartile ranking in both categories for 2023. Positioned in a highly competitive niche, it ranks #18 out of 233 in Immunology and Allergy and #22 out of 236 in Immunology and Microbiology, highlighting its impact within the scientific community. Seminars in Immunopathology publishes comprehensive reviews and research articles, aiming to advance understanding of immune mechanisms in disease and promote interdisciplinary collaboration. Accessible from Germany, this journal is a vital resource for researchers, clinicians, and students seeking to stay at the forefront of immunological advancements and therapeutic innovations.

CURRENT OPINION IN IMMUNOLOGY is a prestigious journal dedicated to the dynamic field of immunology, published by CURRENT BIOLOGY LTD in the United Kingdom. With an ISSN of 0952-7915 and an E-ISSN of 1879-0372, this journal has been a cornerstone of scholarly communication since its inception in 1988 and continues to disseminate cutting-edge research and reviews aimed at advancing our understanding of immune responses. Holding a remarkable Q1 ranking in both Immunology and Allergy categories for 2023, it ranks impressively within the top percentiles in its field, securing 27th233 in Immunology and Allergy and 31st out of 236 in Immunology and Microbiology. Emphasizing high-impact research, the journal provides researchers, professionals, and students with valuable insights into emerging trends and critical developments. As a vital resource in immunological research, it serves as a platform for disseminating innovative findings, fostering collaboration, and enhancing scholarly exchange in a rapidly evolving scientific landscape.

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.

Scandinavian Journal of Immunology is a prestigious peer-reviewed journal published by Wiley, focused on the evolving field of immunology and its interdisciplinary ties with medicine. Since its inception in 1972, this journal has cultivated a rich repository of knowledge, showcasing innovative research and reviews that contribute to the understanding of immune system functions, disorders, and therapeutic interventions. With an impressive impact factor reflecting a Q2 ranking in Immunology and a top-tier Q1 status in miscellaneous Medicine categories for 2023, it is recognized for its high-quality scholarly output, positioning it among the leading journals in the field. Additionally, its Scopus ranking of #84 out of 236 in Immunology underscores its significance and relevance to both emerging and established researchers. Although it does not currently offer open access options, the journal’s expansive reach and rigorous publication standards make it an essential platform for disseminating impactful research to the global scientific community. The journal invites submissions that explore the complexities of the immune system, aiming to bridge clinical and basic science for a comprehensive understanding of immunological phenomena.